SCHEMBL5145886

SCHEMBL5145886

Brc1nc(I)c2[nH]cnc2n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 1/20 0.61
PDPK1 O15530 1/20 0.41
GDA Q9Y2T3 1/20 0.41
DPP4 P27487 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PNP P00491 1/20 0.38
CSNK2A2 P19784 2/20 0.36
CSNK2A1 P68400 2/20 0.36
MEN1 O00255 1/20 0.36
RAB9A P51151 1/20 0.36
CSNK2B P67870 1/20 0.36
KMT2A Q03164 1/20 0.36
DYRK1A Q13627 1/20 0.36
CSNK2A3 Q8NEV1 1/20 0.36
XDH P47989 2/20 0.36
MAP3K5 Q99683 1/20 0.36
ADORA1 P30542 3/20 0.35
ADORA3 P0DMS8 2/20 0.35
ADORA2A P29274 2/20 0.35
PIN1 Q13526 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16146853 0.80 PDPK1 (0.41) CDK2PDPK1GDADPP4ALDH1A1
SCHEMBL533603 0.79 PDPK1 (0.44) CDK2PDPK1GDADPP4ALDH1A1
SCHEMBL532461 0.79 CDK2 (0.66) CDK2PDPK1GDADPP4ALDH1A1
SCHEMBL2997392 0.76 DPP4 (0.61) CDK2PDPK1GDADPP4ALDH1A1
SCHEMBL612211 0.76 GDA (0.41) CDK2PDPK1GDADPP4ALDH1A1
SCHEMBL29873925 0.76 PDPK1 (0.66) CDK2PDPK1GDADPP4PNP
SCHEMBL497199 0.76 PDPK1 (0.66) CDK2PDPK1GDADPP4PNP
SCHEMBL135690 0.76 CDK2 (1.00) CDK2PDPK1GDADPP4MAP3K5
SCHEMBL5935896 0.76 CDK2 (0.61) CDK2PDPK1GDADPP4CSNK2A1
SCHEMBL16146291 0.72 CDK2 (0.45) CDK2PDPK1GDADPP4XDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307167-B2 Production method of 2,6-dihalopurine SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-12-11 US disclosed
EP-1490369-B1 PRODUCTION METHOD OF 2,6-DIHALOPURINE SUMITOMO CHEMICAL CO (JP) 2007-11-14 EP disclosed
CN-1314685-C Process for preparing 2, 6-dihalogenopurine SUMITOMO CHEMICAL CO (JP) 2007-05-09 CN disclosed
CN-1646532-A Process for preparing 2, 6-dihalogenopurine SUMITOMO CHEMICAL CO (JP) 2005-07-27 CN disclosed
US-20050131229-A1 Production method of 2,6-dihalopurine SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-06-16 US disclosed
EP-1490369-A1 PRODUCTION METHOD OF 2,6-DIHALOPURINE Sumitomo Chemical Company, Limited (JP) 2004-12-29 EP disclosed
WO-2003084958-A1 PRODUCTION METHOD OF 2,6-DIHALOPURINE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131229-A1 Production method of 2,6-dihalopurine TPMT, DHPS, DUS2 CDK2 88/4885PDPK1 1702/4885GDA 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.